Pacira Pharm Inc (NQ: PCRX )

16.68 +0.23 (+1.40%)
Streaming Delayed Price Updated: 10:02 AM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira Pharm Inc

< Previous 1 2 3 4 5 6 Next >
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- 
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts
Via Benzinga
Pacira BioSciences Reports Third Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Insights into Pacira BioSciences's Upcoming Earnings
Via Benzinga
Expert Ratings For Pacira BioSciences
Via Benzinga
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
From Pacira BioSciences
Via GlobeNewswire
Where Pacira BioSciences Stands With Analysts
Via Benzinga
Expert Ratings For Pacira BioSciences
Via Benzinga
NASDAQ:PCRX: good value for what you're paying.
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals. 
Via Chartmill
NASDAQ:PCRX, an undervalued stock with good fundamentals.
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
From Pacira BioSciences
Via GlobeNewswire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
In a market where value is scarce, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Pacira BioSciences Reports Second Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
From Pacira BioSciences
Via GlobeNewswire
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Top 5 Health Care Stocks That May Explode In July
Via Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.